Compare CCM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | CTXR |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 18.7M |
| IPO Year | 2009 | 2010 |
| Metric | CCM | CTXR |
|---|---|---|
| Price | $4.77 | $0.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 46.0K | ★ 764.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.47 |
| 52 Week High | $6.98 | $2.19 |
| Indicator | CCM | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 63.60 |
| Support Level | $4.41 | $0.68 |
| Resistance Level | $5.52 | $0.99 |
| Average True Range (ATR) | 0.60 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 39.63 | 82.16 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.